 STAMFORD, Conn., Dec. 28, 2020 GLOBE NEWSWIRE -- Cara Therapeutics, Inc. Nasdaq: CARA, a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that it has submitted a New Drug Application NDA to the U.S. Food and Drug Administration FDA for KORSUVATM Injection difelikefalin for the treatment of moderate-to-severe pruritus in hemodialysis patients. KORSUVA Injection received Breakthrough Therapy Designation from the FDA for this indication. Cara has requested Priority Review for the NDA which, if granted, could result in a six-month review process. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing. 